Table 1.
Summary of the Current Evidence Base for the Effectiveness of Pharmacologic HCM Therapies
| LVOT Gradient Reduction |
Diastolic Dysfunction |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| BB | CCB | Disopyramide | Myosin Inhibitors | BB | CCB | BB Vs CCB | Disopyramide | Myosin Inhibitors | |
| No. of studies | 4 | 4 | 5 | 4 | 4 | 6 | 4 | 5 | 3 |
| No. of randomized trials | 2 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 3 |
| No. of studies published after 2010 | 4 | 0 | 1 | 4 | 3 | 0 | 0 | 1 | 3 |
| Total number of patients studied | 176 | 106 | 167 | 425 | 99 | 130 | 134 | 115 | 408 |
BB = beta-blocker; CCB = calcium-channel blocker; HCM = hypertrophic cardiomyopathy; LVOT = left ventricular outflow tract.